Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast edition of Five Must-Know Things: Pfizer buys into inflammation and immunology; bispecifics and CAR-Ts in the spotlight at ASH; Lilly looks to volume-driven growth; and Novavax talks about diversity in clinical trials.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 17 December 2021, including: Pfizer Inc. buys into inflammation and immunology; bispecifics and CAR-Ts in the spotlight at ASH; Eli Lilly and Company looks to volume-driven growth; and Novavax, Inc. talks about how diversity in clinical trials.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "Pfizer Buys Arena For $6.7bn In Bid To Diversify In Inflammation & Immunology" - Scrip, 13 Dec, 2021.)

(Also see "Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL" - Scrip, 12 Dec, 2021.)

(Also see "Lilly Looks To Volume-Driven Growth In Decade Ahead" - Scrip, 15 Dec, 2021.)

(Also see "For Novavax, Building Trust Was Key To Improving Diversity" - Scrip, 14 Dec, 2021.)


Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts